Cite
HARVARD Citation
Pinto, C. et al. (2021). Gemcitabine with or without ramucirumab as second-line treatment for malignant pleural mesothelioma (RAMES): a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet oncology. 22 (10), pp. 1438-1447. [Online].